
Joan Montero
Research group
- Signal transduction, intracellular compartments and cancer Accredited researcher (R3A-UB)
About me
As an Associate Professor at the University of Barcelona and PI of the “Cell death, Senescence and Cancer Precision Medicine” lab (themonteorlab.com) I am now supervising 4 postdoctoral fellows, and our work consists in developing new tools and discover novel therapies for personalized cancer treatment, collaborating with many oncologists internationally in several exciting translational medicine projects. As a scientist I have published in high-impact journals, I achieved a remarkable impact (h-index: 27 and over 4000 citations), secured funding from competitive sources, and I have been awarded with the Ramon y Cajal, the Annual Spanish National Award for Oncology Research and ICREA Acadèmia
Featured publications
-
HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells
Authors:Reference: Cell Death And Differentiation 2025. -
Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK-rearranged non-small cell lung cancer
Authors:Reference: Cell Death & Disease 2025. -
Microfluidic-based dynamic BH3 profiling predicts anticancer treatment efficacy
Authors:Reference: Npj Precision Oncology 2022. -
Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics
Authors:Reference: Cancer Discovery 2022. -
MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia
Authors:Reference: Frontiers In Cell And Developmental Biology 2021. -
Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance
Authors:Reference: Cell Death & Disease 2020. -
A New CDK9 Inhibitor on the Block to Treat Hematologic Malignancies
Authors:Reference: Clinical Cancer Research 2020. -
Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies
Authors:Reference: Nature Communications 2019. -
Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax
Authors:Reference: Cancer Discovery 2017. -
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Authors:Reference: Cell 2015.
Featured Projects
-
ABT-199 based therapies to treat neuroblastoma
Principal investigator: Juan José Montero BoronatCode: FP00019758_SA001Duration: 01/06/2024 - 31/05/2029 -
Real-time tracking of apoptosis for precision medicine (RTAPREMED)
Principal investigator: Juan José Montero BoronatFunder: Ministerio de Ciencia e InnovaciónCode: PDC2022-133583-I00Duration: 01/12/2022 - 30/11/2024 -
Centralization of pathological diagnosis and implementation of precision medicine strategies in sarcoma.
Principal investigator: Enrique de ÁlavaFunder: Asociación Española Contra el Cáncer (AECC)Duration: 01/11/2022 - 31/10/2025 -
Eliminación selectiva de células senescentes inducidas por terapia para evitar la recaída del cáncer de pulmón.
Principal investigator: Juan José Montero BoronatFunder: Ministerio de Ciencia e Innovación. UniversidadesCode: PID2021-128644OB-I00Duration: 01/09/2022 - 31/08/2025 -
Integrative analysis in dynamic resistance in non-responding relapsed pediatric acute lymphoblastic leukemia patients
Code: DJCLS 19R/2022Duration: 01/09/2022 - 31/08/2025